Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

HIV Drug Resistance in Resource-limited Countries: Threat for HIV Elimination.

Ngo-Giang-Huong N, Aghokeng AF.

EClinicalMedicine. 2019 Apr 1;9:3-4. doi: 10.1016/j.eclinm.2019.03.013. eCollection 2019 Mar. No abstract available.

2.

Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications.

Jourdain G, Ngo-Giang-Huong N, Khamduang W.

Infect Drug Resist. 2019 Apr 26;12:977-987. doi: 10.2147/IDR.S171695. eCollection 2019.

3.

Feasibility of using dried blood spots for HIV viral load testing among HIV-infected individuals in Thailand using QIAGEN QIAsymphony-artus HIV-1 platform.

Thepbundit V, Ngo-Giang-Huong N, Salvadori N, Laolue A, Kunyanone N, Sata-Un J, Jourdain G, Sirirungsi W, Khamduang W.

J Med Virol. 2019 May 16. doi: 10.1002/jmv.25506. [Epub ahead of print]

PMID:
31095748
4.

Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study.

Latthaphasavang V, Vanhems P, Ngo-Giang-Huong N, Sibounlang P, Paboriboune P, Malato L, Keoluangkhot V, Thammasack S, Salvadori N, Khamduang W, Steenkeste N, Trépo C, Dény P, Jourdain G.

PLoS One. 2019 Apr 24;14(4):e0215011. doi: 10.1371/journal.pone.0215011. eCollection 2019.

5.

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.

Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, Siberry GK, Jourdain G.

Clin Infect Dis. 2019 Jun 18;69(1):144-146. doi: 10.1093/cid/ciy982.

PMID:
30924492
6.

Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.

Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni TD, Maiga AI, Kania D, Eymard-Duvernay S, Peeters M, Soulie C, Peytavin G, Rekacewicz C, Chaix ML, Aghokeng AF; ANRS 12333 Study Group .

J Antimicrob Chemother. 2019 Feb 1;74(2):462-467. doi: 10.1093/jac/dky443.

7.

Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study.

Ségéral O, N'Diaye DS, Prak S, Nouhin J, Chhun S, Khamduang W, Chim K, Roque-Afonso AM, Piola P, Borand L, Ngo-Giang-Huong N, Rouet F; ANRS 12328 12345 Study Group.

J Clin Virol. 2018 Dec;109:29-34. doi: 10.1016/j.jcv.2018.10.007. Epub 2018 Oct 22.

PMID:
30388664
8.

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siriwachirachai T, Putiyanun C, Suriyachai P, Tierney C, Salvadori N, Chinwong D, Decker L, Tawon Y, Murphy TV, Ngo-Giang-Huong N, Siberry GK, Jourdain G; iTAP Study Team.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01686-18. doi: 10.1128/AAC.01686-18. Print 2018 Dec.

9.

Tenofovir to Prevent Perinatal Transmission of Hepatitis B.

Jourdain G, Ngo-Giang-Huong N, Harrison L; iTAP Study Group.

N Engl J Med. 2018 Jun 14;378(24):2350. doi: 10.1056/NEJMc1805396. No abstract available.

PMID:
29897855
10.

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N.

N Engl J Med. 2018 Mar 8;378(10):911-923. doi: 10.1056/NEJMoa1708131.

11.

Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in Thailand.

Traisathit P, Delory T, Ngo-Giang-Huong N, Somsamai R, Techakunakorn P, Theansavettrakul S, Kanjanavanit S, Mekmullica J, Ngampiyaskul C, Na-Rajsima S, Lallemant M, Cressey TR, Jourdain G, Collins IJ, Le Coeur S.

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):17-22. doi: 10.1097/QAI.0000000000001571.

12.

Genetic analyses of HIV env associated with uveitis in antiretroviral-naive individuals.

Williams-Wietzikoski CA, So ID, Bull ME, Samleerat T, Pathanapitoon K, Kunavisarut P, Kongyai N, Ngo-Giang-Huong N, Frenkel LM, Sirirungsi W.

AIDS. 2017 Aug 24;31(13):1825-1830. doi: 10.1097/QAD.0000000000001550.

13.

Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.

Hongjaisee S, Braibant M, Barin F, Ngo-Giang-Huong N, Sirirungsi W, Samleerat T.

AIDS Res Hum Retroviruses. 2017 Sep;33(9):946-951. doi: 10.1089/AID.2017.0044. Epub 2017 Jun 12.

14.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.

Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW.

EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.

15.

Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.

Guinoiseau T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, Brulard C, Vourc'h P, Goudeau A, Gaudy-Graffin C.

PLoS One. 2017 Mar 31;12(3):e0174852. doi: 10.1371/journal.pone.0174852. eCollection 2017.

16.

Human Papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand.

Delory T, Ngo-Giang-Huong N, Rangdaeng S, Chotivanich N, Limtrakul A, Putiyanun C, Suriyachai P, Matanasarawut W, Jarupanich T, Liampongsabuddhi P, Heard I, Jourdain G, Lallemant M, Le Coeur S; PapilloV study group.

J Infect. 2017 May;74(5):501-511. doi: 10.1016/j.jinf.2017.02.007. Epub 2017 Feb 28.

PMID:
28254419
17.

Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy.

Salvadori N, Ngo-Giang-Huong N, Duclercq C, Kanjanavanit S, Ngampiyaskul C, Techakunakorn P, Puangsombat A, Figoni J, Mary JY, Collins IJ, Cressey TR, Le Cœur S, Sirirungsi W, Lallemant M, McIntosh K, Jourdain G.

J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):161-167. doi: 10.1093/jpids/piw090.

18.

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.

Ngo-Giang-Huong N, Wittkop L, Judd A, Reiss P, Goetghebuer T, Duiculescu D, Noguera-Julian A, Marczynska M, Giacquinto C, Ene L, Ramos JT, Cellerai C, Klimkait T, Brichard B, Valerius N, Sabin C, Teira R, Obel N, Stephan C, de Wit S, Thorne C, Gibb D, Schwimmer C, Campbell MA, Pillay D, Lallemant M; EuroCoord-CHAIN-EPPICC joint project study group.

BMC Infect Dis. 2016 Nov 8;16(1):654.

19.

Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis.

Leroi C, Adam P, Khamduang W, Kawilapat S, Ngo-Giang-Huong N, Ongwandee S, Jiamsiri S, Jourdain G.

Int J Infect Dis. 2016 Oct;51:36-43. doi: 10.1016/j.ijid.2016.08.017. Epub 2016 Aug 28. Review.

20.

Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.

Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, Khamduang W, Bowonwatanuwong C, Puthanakit T, Siberry GK, Watts DH, Murphy TV, Achalapong J, Hongsiriwon S, Klinbuayaem V, Thongsawat S, Chung RT, Pol S, Chotivanich N.

BMC Infect Dis. 2016 Aug 9;16:393. doi: 10.1186/s12879-016-1734-5.

21.

Early infant HIV diagnosis and entry to HIV care cascade in Thailand: an observational study.

Sirirungsi W, Khamduang W, Collins IJ, Pusamang A, Leechanachai P, Chaivooth S, Ngo-Giang-Huong N, Samleerat T.

Lancet HIV. 2016 Jun;3(6):e259-65. doi: 10.1016/S2352-3018(16)00045-X. Epub 2016 May 3.

22.

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.

Beck IA, Payant R, Ngo-Giang-Huong N, Khamduang W, Laomanit L, Jourdain G, Frenkel LM.

J Virol Methods. 2016 Jul;233:51-5. doi: 10.1016/j.jviromet.2016.03.014. Epub 2016 Mar 26.

23.

Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.

Gantt S, Leister E, Jacobsen DL, Boucoiran I, Huang ML, Jerome KR, Jourdain G, Ngo-Giang-Huong N, Burchett S, Frenkel L.

J Med Virol. 2016 Jun;88(6):1051-8. doi: 10.1002/jmv.24420. Epub 2015 Nov 18.

24.

Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.

Sripan P, Le Coeur S, Ingsrisawang L, Cressey TR, Bouazza N, Foissac F, Ngo-Giang-Huong N, Traisathit P, Srirompotong U, Ayudhaya OP, Puangsombat A, Jungpipun J, Jittayanun K, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

Antivir Ther. 2016;21(5):435-40. doi: 10.3851/IMP3001. Epub 2015 Oct 22.

25.

Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.

Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators.

AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.

26.

Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

PLoS One. 2015 Aug 28;10(8):e0137368. doi: 10.1371/journal.pone.0137368. eCollection 2015. No abstract available.

27.

Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.

Olson SC, Ngo-Giang-Huong N, Beck I, Deng W, Britto P, Shapiro DE, Bumgarner RE, Mullins JI, Van Dyke RB, Jourdain G, Frenkel LM.

AIDS. 2015 Jul 31;29(12):1467-71. doi: 10.1097/QAD.0000000000000737.

28.

Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

PLoS One. 2015 Jun 26;10(6):e0130917. doi: 10.1371/journal.pone.0130917. eCollection 2015. No abstract available.

29.

Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

PLoS One. 2015 May 19;10(5):e0126647. doi: 10.1371/journal.pone.0126647. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0130917. PLoS One. 2015;10(8):e0137368.

30.

New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand.

Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, Techapornroong M, Bowonwatanuwong C, Kantipong P, Nilmanat A, Yutthakasemsunt N, Chutanunta A, Thongpaen S, Klinbuayaem V, Decker L, Le Cœur S, Lallemant M, Capeau J, Mary JY, Jourdain G.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):453-9. doi: 10.1097/QAI.0000000000000647.

PMID:
25886928
31.

Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.

Suaysod R, Ngo-Giang-Huong N, Salvadori N, Cressey TR, Kanjanavanit S, Techakunakorn P, Krikajornkitti S, Srirojana S, Laomanit L, Chalermpantmetagul S, Lallemant M, Le Cœur S, McIntosh K, Traisathit P, Jourdain G.

Clin Infect Dis. 2015 Jul 1;61(1):95-101. doi: 10.1093/cid/civ271. Epub 2015 Apr 1.

PMID:
25838288
32.

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.

Sirirungsi W, Urien S, Harrison L, Kamkon J, Tawon Y, Luekamlung N, Thongpaen S, Nilmanat A, Jourdain G, Lallemant M, Le Coeur S, Ngo-Giang-Huong N, Owen A, Cressey TR.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e56-9. doi: 10.1097/QAI.0000000000000504. No abstract available.

33.

Estimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution model.

Chaillon A, Samleerat T, Zoveda F, Ballesteros S, Moreau A, Ngo-Giang-Huong N, Jourdain G, Gianella S, Lallemant M, Depaulis F, Barin F.

PLoS One. 2014 Apr 9;9(4):e90421. doi: 10.1371/journal.pone.0090421. eCollection 2014.

34.

Cost-effectiveness of early infant HIV diagnosis of HIV-exposed infants and immediate antiretroviral therapy in HIV-infected children under 24 months in Thailand.

Collins IJ, Cairns J, Ngo-Giang-Huong N, Sirirungsi W, Leechanachai P, Le Coeur S, Samleerat T, Kamonpakorn N, Mekmullica J, Jourdain G, Lallemant M; Programme for HIV Prevention and Treatment Study Team.

PLoS One. 2014 Mar 14;9(3):e91004. doi: 10.1371/journal.pone.0091004. eCollection 2014.

35.

Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.

Monleau M, Aghokeng AF, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Touré-Kane C, Truong LX, Chaix ML, Delaporte E, Ayouba A, Peeters M; ANRS 12235 Study Group.

J Clin Microbiol. 2014 Feb;52(2):578-86. doi: 10.1128/JCM.02860-13. Epub 2013 Dec 11.

36.

Association between lymphocyte and monocyte subsets and cognition in children with HIV.

Ananworanich J, Bunupuradah T, Apornpong T, Kosalaraksa P, Hansudewechakul R, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Ngo-Giang-Huong N, Jaimulwong T, Kerr SJ, Brouwers P, Shearer WT, Puthanakit T; PREDICT Study Group.

AIDS Res Ther. 2014 Jan 22;11(1):7. doi: 10.1186/1742-6405-11-7.

37.

Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.

Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E, Chaix ML, Peeters M, Ayouba A; ANRS 12186 Study Group.

Clin Infect Dis. 2014 Jan;58(1):99-109. doi: 10.1093/cid/cit627. Epub 2013 Sep 27.

PMID:
24076968
38.

Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.

Nouhin J, Madec Y, Ngo-Giang-Huong N, Ferradini L, Nerrienet E.

PLoS One. 2013 Aug 28;8(8):e73744. doi: 10.1371/journal.pone.0073744. eCollection 2013.

39.

Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.

Jourdain G, Le Cœur S, Ngo-Giang-Huong N, Traisathit P, Cressey TR, Fregonese F, Leurent B, Collins IJ, Techapornroong M, Banchongkit S, Buranabanjasatean S, Halue G, Nilmanat A, Luekamlung N, Klinbuayaem V, Chutanunta A, Kantipong P, Bowonwatanuwong C, Lertkoonalak R, Leenasirimakul P, Tansuphasawasdikul S, Sang-A-Gad P, Pathipvanich P, Thongbuaban S, Wittayapraparat P, Eiamsirikit N, Buranawanitchakorn Y, Yutthakasemsunt N, Winiyakul N, Decker L, Barbier S, Koetsawang S, Sirirungsi W, McIntosh K, Thanprasertsuk S, Lallemant M; PHPT-3 study team.

PLoS Med. 2013 Aug;10(8):e1001494. doi: 10.1371/journal.pmed.1001494. Epub 2013 Aug 6.

40.

Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring.

Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Borkird T, Layangool P, Kamonpakorn N, Jitphiankha W, Kwanchaipanich R, Potchalongsin S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment (PHPT) group.

J Clin Virol. 2013 Oct;58(2):415-21. doi: 10.1016/j.jcv.2013.06.025. Epub 2013 Aug 2.

41.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

42.

Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women.

Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, Jourdain G, Suwankornsakul W, Jarupanich T, Chalermpolprapa V, Nanta S, Puarattana-Aroonkorn N, Tonmat S, Lallemant M, Goudeau A, Sirirungsi W; Program for HIV Prevention and Treatment (PHPT-2) group.

Clin Infect Dis. 2013 Jun;56(12):1704-12. doi: 10.1093/cid/cit166. Epub 2013 Mar 13.

43.

Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial.

Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, Kerr SJ, Kanjanavanit S, Ngampiyaskul C, Wongsawat J, Luesomboon W, Ngo-Giang-Huong N, Chettra K, Cheunyam T, Suwarnlerk T, Ubolyam S, Shearer WT, Paul R, Mofenson LM, Fox L, Law MG, Cooper DA, Phanuphak P, Vun MC, Ruxrungtham K; PREDICT Study Group.

Lancet Infect Dis. 2012 Dec;12(12):933-41. doi: 10.1016/S1473-3099(12)70242-6. Epub 2012 Oct 9.

44.

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group.

PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.

45.

Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.

Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Luekamlung N, Halue G, Buranawanitchakorn Y, Kunkongkapan S, Buranabanjasatean S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment Study Group.

PLoS One. 2012;7(7):e42184. Epub 2012 Jul 31.

46.

Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties.

Thenin S, Samleerat T, Tavernier E, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Barin F, Braibant M.

Virology. 2012 Apr 25;426(1):12-21. doi: 10.1016/j.virol.2012.01.017. Epub 2012 Feb 4.

47.

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, Beck IA, Yuthavisuthi P, Prommas S, Puthanakit T, Achalapong J, Chotivanich N, Rasri W, Cressey TR, Maupin R, Mirochnick M, Jourdain G; IMPAACT P1032 Protocol Team.

Clin Infect Dis. 2012 Jan 15;54(2):285-93. doi: 10.1093/cid/cir798. Epub 2011 Dec 5.

48.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

49.

The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers.

Khamduang W, Jourdain G, Sirirungsi W, Layangool P, Kanjanavanit S, Krittigamas P, Pagdi K, Somsamai R, Sirinontakan S, Hinjiranandana T, Ardonk W, Hongsiriwon S, Nanta S, Borkird T, Lallemant M, McIntosh K, Ngo-Giang-Huong N; Program for HIV Prevention and Treatment (PHPT) Study Group.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):188-92. doi: 10.1097/QAI.0b013e31822d0433.

50.

Current challenges to viral load testing in the context of emerging genetic diversity of HIV-1.

Rouet F, Liégeois F, Mouinga-Ondémé A, Kania D, Viljoen J, Wambua S, Ngo-Giang-Huong N, Ménan H, Peeters M, Nerrienet E.

Expert Opin Med Diagn. 2011 May;5(3):183-202. doi: 10.1517/17530059.2011.566860. Epub 2011 Mar 29.

PMID:
23484497

Supplemental Content

Loading ...
Support Center